• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Clearmind Medicine Inc. - Common Shares (NQ:CMND)

    5.870 -0.130 (-2.17%)
    Delayed Quote Updated: 3:48 PM EDT, Oct 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 8,418
    Open 6.255
    Bid (Size) 5.380 (100)
    Ask (Size) 7.160 (300)
    Prev. Close 6.000
    Today's Range 5.870 - 6.255
    52wk Range 0.7055 - 480.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
    From Clearmind Medicine Inc.
    Via GlobeNewswire

    Performance

    52-Week Range 98.8% below 52-week high
    5.870
    0.7152W Low 480.0052W High
    1 Week 7.7% below 1-week high
    5.871W Low 6.361W High

    Clearmind Medicine Inc. - Common Shares (CMND) traded between $0.71 and $480.00 over the past 52 weeks and last traded at $5.87, 98.8% below its 52-week high. Over the past week it ranged between $5.87 and $6.36.

    Past 12 Months
    -2.2%
    +590.6%
    +264.6%
    -27.7%
    -70.5%
    -98.5%
    1W -$0.13
    1M +$5.02
    3M +$4.26
    6M -$2.25
    YTD -$14.03
    1Y -$387.05

    CMND was -98.5% over the past year, -27.7% over six months, -70.5% year to date, -2.2% in the last week.

    12 Months vs Market
    CMND
    -98.5%
    DIA
    +11.6%
    SPY
    +13.1%
    QQQ
    +15.4%
    IWM
    +11.9%

    Over the past 12 months CMND returned -98.5% versus DIA (Dow) +11.6%, SPY (S&P 500) +13.1%, QQQ (Nasdaq 100) +15.4% and IWM (Russell 2000) +11.9%.

    Volume & Liquidity 0.02× 3-mo avg
    Today 8,418 3-mo avg 422.9K
    1W
    6.9K
    1M
    62.1K
    3M
    422.9K
    6M
    1.2M
    YTD
    890.7K
    1Y
    730.2K

    CMND most recently traded 8,418 shares against a 3-month average daily volume of 422.9K.

    More News

    Read More
    News headline image
    Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio
    Via TheNewswire.com
    Topics Intellectual Property
    News headline image
    Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Unusual volume stocks in Tuesday's session ↗
    Via Chartmill
    News headline image
    Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Which stocks are experiencing notable movement on Friday? ↗
    Via Chartmill
    News headline image
    Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    What's going on in today's pre-market session ↗
    Via Chartmill
    News headline image
    Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
    From Clearmind Medicine Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Clearmind Medicine Inc. - Common Shares publicly traded?
    Yes, Clearmind Medicine Inc. - Common Shares is publicly traded.
    What exchange does Clearmind Medicine Inc. - Common Shares trade on?
    Clearmind Medicine Inc. - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Clearmind Medicine Inc. - Common Shares?
    The ticker symbol for Clearmind Medicine Inc. - Common Shares is CMND on the Nasdaq Stock Market
    What is the current price of Clearmind Medicine Inc. - Common Shares?
    The current price of Clearmind Medicine Inc. - Common Shares is 5.870
    When was Clearmind Medicine Inc. - Common Shares last traded?
    The last trade of Clearmind Medicine Inc. - Common Shares was at 10/23/26 03:48 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.